At the news
? BULLISHIMPACT 6/10 8-K filed Jul 24, 2026 at 11:58 ET
Profound Medical announced new CAPTAIN trial data showing statistically significant superior penile length preservation with the TULSA Procedure vs robotic radical prostatectomy (no median change vs 0.65 cm reduction at 1 month, p<0.001). This adds to previously reported safety endpoint advantages in erectile function and urinary continence, strengthening the clinical value proposition for TULSA.
- CAPTAIN trial: no median change in penile length at 1 month after whole-gland TULSA vs 0.65 cm median reduction after robotic RP
- Between-arm difference statistically significant (0.42 cm, p<0.001)
- Data presented at Society of Robotic Surgery Annual Meeting, July 24, 2026
- Previously announced CAPTAIN primary safety endpoint showed TULSA superiority in preserving erectile function and urinary continence at 6 months
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access